A detailed history of Lokken Investment Group LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lokken Investment Group LLC holds 5,109 shares of BMY stock, worth $295,095. This represents 0.12% of its overall portfolio holdings.

Number of Shares
5,109
Previous 5,178 1.33%
Holding current value
$295,095
Previous $215,000 22.79%
% of portfolio
0.12%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$39.66 - $51.75 $2,736 - $3,570
-69 Reduced 1.33%
5,109 $264,000
Q2 2024

Aug 09, 2024

BUY
$40.25 - $52.99 $5,393 - $7,100
134 Added 2.66%
5,178 $215,000
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $1,439 - $1,632
30 Added 0.6%
5,044 $273,000
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $193 - $231
4 Added 0.08%
5,014 $257,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $2,605 - $2,912
45 Added 0.91%
5,010 $290,000
Q2 2023

Aug 09, 2023

BUY
$63.71 - $70.74 $25,356 - $28,154
398 Added 8.71%
4,965 $317,000
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $73,398 - $83,250
1,117 Added 32.38%
4,567 $316,000
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $1,164 - $1,378
17 Added 0.5%
3,450 $248,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $2 - $1,306
17 Added 0.5%
3,433 $244,000
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $1,161 - $1,279
16 Added 0.47%
3,416 $263,000
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $3,750 - $4,496
-61 Reduced 1.76%
3,400 $256,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $185,613 - $216,381
3,461 New
3,461 $216,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Lokken Investment Group LLC Portfolio

Follow Lokken Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lokken Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lokken Investment Group LLC with notifications on news.